The aim of the paper is to analyse the relationships between the openness degree of companies and their I) context features, 2) R & D organization and 3) financial performances. The openness degree is defined after a pecuniary approach, involving all the transactions in the innovation market. Hypotheses are formulated and, then, tested on a sample of I26 world top R & D spending bio-pharmaceutical companies for the period 2008-20I2. Open innovation is more pervasive among small and young companies, for most of which it represents the very core business. Inbound and outbound practices have a similar diffusion in terms of number of companies adopting them, but the cumulative values of inbound flows are higher, whereas outbound flows are more relevant when compared to the total business of the firms. Inbound practices are substitutive to internal R & D activities, while outbound ones are complementary to internal development. The performances of companies have an inverted-U shape trend versus inbound practices and a fundamentally decreasing trend versus outbound ones.
15 August 2014 in Creativity and Innovation Management
This paper aims at investigating the relationships between the adoption of open innovation by companies and their context features, internal R&D, and financial performances. Two proxies for openness-variety and intensity-are defined, and six hypotheses are formulated and tested on a sample of 68 worldwide top R&D spending pharmaceutical companies. The period of 2008-2012 was analyzed for a total of 340 statistical units. Our results suggest that open innovation is a very pervasive behavior among smaller and younger companies, for which internal R&D is complementary to openness; still being in the development phase, they derive most of their revenues from open innovation itself and show negative financial performances. Yet, a wider range of open transactions are performed by larger and longer established firms, exhibiting good financial performances and adopting open innovation as a substitution to internal R&D efforts. Through an in-depth review of the literature, this paper contributes to the research on open innovation by providing an accounting measurement system, testing six hypotheses among open innovation and some firm-level variables, and positioning the obtained results within the current debate.
1 January 2014 in International Journal of Intelligent Enterprise
The paper suggests a methodology for measuring companies' openness degree through accounting data and providing a relation between open innovation activities and intellectual capital components. Four openness dimensions are defined and a synthetic measure of openness is suggested. The model is applied to a sample of 126 world top R&D spending companies in the bio-pharmaceutical industry for the period 2008-2012. Results show a negative correlation of openness with firm age, dimension and efficiency and a positive correlation with R&D intensity, with biotech companies being more open than pharmaceutical ones. Further, the most relevant component of openness is represented by the revenues deriving from joint development projects, out-licensing and R&D outsourcing. The paper contributes to the existing research by suggesting inbound and outbound metrics for open innovation and by underlining the role of intellectual capital. The framework can be used for monitoring and benchmarking the openness degree of companies with competitors.
1 January 2015 in International Journal of Technology Management
The paper suggests an accounting-based framework for defining open innovation adoption modalities through the analysis of annual reports. Five models are described, depending on the costs, revenues, new investments and divestments in intangibles and knowledge assets related to open innovation. The framework is applied to a sample of 271 world top research and development (R&D) spending companies in the bio-pharmaceutical and the technology hardware and equipment industries. Annual reports data are examined for the period 2010-2012, with 813 statistical units analysed after a cross-section perspective. Results show that bio-pharmaceutical companies are twice open than technology hardware and equipment firms; the former mainly adopt a collaborative model for open innovation, by jointly developing research programmes with external parties, the latter prefer to incorporate other companies through the use of spin-ins. The paper contributes to the existing research by suggesting a pecuniary approach to evaluate open innovation adoption modalities. The framework can be used by companies for both monitoring their own open innovation positioning and benchmarking it with those of competitors.
1 July 2015 in Journal of technology management & innovation
This study provides a patent-based framework, investigating the relationship among the relevance of the technological domains, the exploitation vs. exploration strategies and the choice of open innovation practices. Specifically, this work presents five levels of open innovation adoption and analyses the reason why firms open up their innovation boundaries. The methodology is tested on a sample of 240 companies belonging to the bio-pharmaceutical and the technology hardware & equipment industries, by examining their patents filed in 2011. Results show that the relevance of the knowledge domain affects the choice of the innovation strategy; also, non-equity alliances are preferred in explorative activities and equity alliances in exploitative ones.